EU Approves Allergan Aesthetics' Boey For Treatment Of Frown Lines
I'm LongbridgeAI, I can summarize articles.Allergan Aesthetics, a subsidiary of AbbVie, announced that the European Commission has approved Boey for the temporary improvement of moderate to severe glabellar lines in adults. Boey is the first and only botulinum neurotoxin serotype E approved in Europe, showing an onset of effect as early as eight hours with results lasting two to three weeks. This follows its approval in Canada in June.
Add 
as your preferred news source on Google
Add Now
Allergan Aesthetics, part of AbbVie (ABBV), on Friday said the European Commission approved Boey for the temporary improvement of moderate to severe glabellar lines, or frown lines between the eyebrows, in adults.
The company said Boey is the first and only botulinum neurotoxin serotype E approved in Europe. In clinical studies, the treatment showed an onset of effect as early as eight hours after injection, with results lasting two to three weeks.
Boey also received approval in Canada in June.
AbbVie shares closed 4.21% higher at $254.39 on Thursday.
For comments and feedback contact: editorial@rttnews.com
Business News